ACADIA Pharmaceuticals Inc (ACAD)
Cash ratio
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 319,589 | 155,149 | 177,134 | 204,745 | 188,657 | 98,193 | 107,941 | 290,895 | 114,846 | 154,842 | 139,833 | 204,920 | 147,435 | 94,640 | 266,956 | 304,487 | 326,028 | 452,352 | 310,441 | 173,059 |
Short-term investments | US$ in thousands | 436,404 | 410,181 | 323,808 | 265,775 | 250,208 | 247,727 | 267,437 | 111,978 | 301,977 | 281,737 | 296,518 | 241,057 | 373,271 | 445,651 | 289,962 | 273,281 | 305,930 | 192,089 | 348,110 | 478,347 |
Total current liabilities | US$ in thousands | 394,870 | 343,945 | 337,851 | 330,597 | 254,254 | 209,603 | 187,942 | 224,301 | 125,630 | 116,570 | 117,681 | 119,603 | 96,068 | 88,218 | 95,328 | 109,373 | 105,967 | 91,856 | 86,422 | 99,741 |
Cash ratio | 1.91 | 1.64 | 1.48 | 1.42 | 1.73 | 1.65 | 2.00 | 1.80 | 3.32 | 3.75 | 3.71 | 3.73 | 5.42 | 6.12 | 5.84 | 5.28 | 5.96 | 7.02 | 7.62 | 6.53 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($319,589K
+ $436,404K)
÷ $394,870K
= 1.91
ACADIA Pharmaceuticals Inc's cash ratio has fluctuated over the years based on the provided data. The cash ratio represents the company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger liquidity position.
From March 31, 2020, to June 30, 2021, the cash ratio gradually increased from 6.53 to 7.62, reflecting an improvement in the company's ability to meet its short-term obligations with cash on hand. However, from March 31, 2021, to December 31, 2024, the cash ratio experienced a declining trend, dropping to as low as 1.42 by March 31, 2024.
The decreasing cash ratio may signal potential liquidity challenges for ACADIA Pharmaceuticals Inc as it indicates a decreasing ability to cover its short-term liabilities with available cash. It is important for the company to closely monitor its cash position and manage its liquidity effectively to ensure it can meet its financial obligations and fund its operations.
Peer comparison
Dec 31, 2024